Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation.
Mak
Koon-Hou
KH
D000077284:Abciximab; D000208:Acute Disease; D017130:Angioplasty; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology*; D003327:Coronary Disease / Q000188:drug therapy* / Q000378:metabolism; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000494:pharmacology*; D009203:Myocardial Infarction / Q000188:drug therapy / Q000601:surgery; D010314:Partial Thromboplastin Time; D011516:Prothrombin / Q000187:drug effects* / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic; D013917:Thrombin / Q000096:biosynthesis*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D011516:Prothrombin; D013917:Thrombin; D010959:Tissue Plasminogen Activator; D000077284:Abciximab